A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

Официальное название

A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SCTB35 in Patients with Systemic Lupus Erythematosus

Обзор

This study is a multicenter Phase Ib/II clinical trial aimed at evaluating the safety, tolerability and efficacy of SCTB35 in patients with systemic lupus erythematosus (SLE).

Подробное описание

This study contains the dose-escalation and dose-expansion parts. The escalation cohorts will be enrolled to explore the maximum tolerated dose and recommended phase II dose (RP2D). A Safety Review Committee (SRC) will review the accumulated safety data and other available data, and make a recommendation to each dose level of SCTB35 in the escalation cohorts. The expansion cohorts will be initiated after the RP2D is confirmed, and to further compare the preliminary efficacy and safety of SCTB35 at appropriate dose levels recommended by SRC.

Вмешательства

• Биопрепарат SCTB35 injection
  SCTB35 will be subcutaneously administered at a dose as specified in the respective dose-escalation cohorts. Then, the RP2D and other appropriate doses of SCTB35 will be applied for the dose-expansion cohorts.

Первичные конечные точки

• Dose-escalation part： Incidence rate of adverse event (AE) [Срок оценки: From first dose to the 24 weeks]
• Dose-expansion part：SRI-4 [Срок оценки: Up to Week 24]

Вторичные конечные точки (7)

• Dose-escalation part： SLEDAI-2K [Срок оценки: Up to week 12, 24]
• Dose-escalation part： physician global assessment (PGA) [Срок оценки: Up to week 12, 24]
• Dose-escalation part：Immunogenicity； [Срок оценки: From baseline to Week 24]
• Dose-expansion part：SLEDAI-2K [Срок оценки: Up to week 12, 24]
• Dose-expansion part： BILAG [Срок оценки: Up to week 12, 24]
• Dose-expansion part： PGA [Срок оценки: Up to week 12, 24]
• Dose-expansion part： SFI [Срок оценки: Up to week 52]

Критерии участия

Критерии включения

• Age 18-75 years；
• Diagnosed with SLE for ≥12 weeks prior to screening (2019-ACR/EULAR criteria);
• SLEDAI-2K ≥ 8 at screening, or ≥6 if there is hypocomplementemia or elevated anti-dsDNA antibody levels;
• Positive for ANA (1:80) or positive for anti-dsDNA and/or anti-Sm antibodies within the last 12 months or at screening;
• Currently receiving ≥1 stable dose of standard treatment: oral corticosteroids, antimalarials, or conventional immunosuppressive drugs

• Stable corticosteroid dose for ≥4 weeks prior to baseline;
• Stable dose of antimalarial drugs for ≥4 weeks prior to baseline;
• Stable dose of immunosuppressive agents for ≥4 weeks prior to baseline;
• All male participants or females of reproductive potential must agree to use reliable contraception with their partner from signing the ICF through 6 months after the last dose of the study drug;
• Understanding of the study procedures and voluntary signing of the informed consent form.

Критерии исключения

• Severe active or unstable lupus-related neuropsychiatric disorders;
• Other autoimmune diseases that may interfere with efficacy evaluation;
• Catastrophic antiphospholipid syndrome;
• Received treatments that may affect the drug's effect:
• Received live vaccines or attenuated vaccines within 28 days prior to baseline or screening;
• Clinically significant bleeding risk;
• Abnormal laboratory results:

• AST or ALT >2.5 x ULN;
• Total bilirubin >1.5 x ULN;
• ANC <1.5x10⁹/L;
• Platelets <75x10⁹/L;
• Hemoglobin <100g/L;
• eGFR <30 mL/min/1.73 m²;
• Positive serum HCG;
• Received any investigational treatment within 30 days prior to baseline or within 5 half-lives of the investigational drug (whichever is longer);
• Participants with recurrent, chronic, or other active infections as assessed by the investigator;
• Severe or uncontrolled disease, which would prevent participation in the study;
• Positive viral serology tests, including HIV, HCV, and HBV;
• Tuberculosis screening: Known active tuberculosis or latent tuberculosis infection (LTBI);
• Any type of active infection except nail bed fungal infections;
• Severe infections;
• History of progressive multifocal leukoencephalopathy (PML);
• Diagnosed with type 1 or type 2 diabetes with poor control;
• Uncontrolled hypertension (systolic >140 mmHg or diastolic >90 mmHg);
• History of malignancy within 5 years prior to baseline;
• Alcohol abuse or drug misuse within 12 months prior to screening;
• Intolerance to the study drug or contraindications, including a history of severe allergic reactions to monoclonal antibodies or any component of SCTB35 injection;
• Required hospitalization for major surgery within 4 weeks prior to screening or within 12 weeks post-study drug administration;
• Participants with mental disorders or poor compliance;
• Severe lupus nephritis;
• History of solid organ or hematopoietic stem cell/bone marrow transplant, or expected to undergo transplant surgery during the study;
• Pregnant or breastfeeding;
• Any other condition that the investigator deems unsuitable for participation in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Не применимо

Модель

Одна группа

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 14 центров

• Peking Union Medical College Hospital, Chinese Academy of Medical Sciences — Пекин
• Xuanwu Hospital, Capital Medical University — Пекин
• Jilin Provincial People's Hospital — Changchun
• Guangdong Provincial People's Hospital — Гуанчжоу
• Zhejiang Provincial People's Hospital — Ханчжоу
• The First People's Hospital of Jiujiang City — Jiujiang
• The First Affiliated Hospital of Kunming Medical University — Куньмин
• Linfen Central Hospital — Linfen
• … и ещё 6 центров

Идентификаторы

NCT: NCT06841042 · SCTB35-X201

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗